2019Research Open (London South Bank University)Open access

Cisplatin augments the anti-schistosomal effect of praziquantel in a schistosoma-infected cancer model

Mohamed L. Salem, Afrah F. Salama, Afnan H. El‐Gowily, Mohammed A. Mansour, Mohammed Mahmud Ali El-Said

Open full text 1 citations

Abstract

Schistosomiasis is the third most devastating tropical disease worldwide caused by blood flukes of the genus\nSchistosoma. Praziquantel (PZQ) is the drug of choice for treating all species of schistosomes. However, PZQ kills only\nadult Schistosoma worms, not immature stages. The inability of PZQ to abort early infection or prevent re-infection, and\nthe lack of prophylactic effect prompt the need for novel drugs and strategies for the prevention of schistosomiasis.\nTumor burden can be developed in Schistosoma-infected patients. The present study aimed to determine the host\nresponses to mutual interaction between cancer, represented by Ehrlich ascites, and infection, represented\nby Schistosomiasis. Mice infected with Schistosoma and challenged with tumor 4-5 weeks later showed the same\nanti-schistosomal (worm and egg burden) and antitumor (total tumor cell count and mouse survival) parameters\nwhen compared to mice infected with Schistosoma alone or challenged with tumor cells alone. As expected,\ncombinatorial treatment with PZQ and cisplatin of Schistosoma-infected mice that were challenged with tumor cell\nline decreased the tumor burden as well as the worm and egg burden after treatment as compared to the non-treated\ncontrols; while the worm burden and egg counts were significantly decreased (P <0.001) in treated group (VI) treated\nwith cisplatin (0.5 mg/kg), group (VII) treated with cisplatin (2 mg/kg), group (VIII) treated with PZQ/ cisplatin\n(0.5 mg/kg) and group (IX) treated with PZQ / cisplatin (2 mg/kg) by 44.55% , 74%, 100% and 97.8% in worm burden,\nand by 47%, 78.7%, 96% and 97% in liver egg count , respectively than that of group (II) non treated S. mansoni\ninfected alone and (IV) non treated S. mansoni/EAC alone. Also, Group IX caused a significant reduction\n(P <0.05) in worm burden than that of group VI. Also, total ascetic volume and the tumor cell counts in Ehrlich's\nascites carcinoma (EAC)-cells were significantly decreased (P <0.001) in groups VIII and IX than that of the group (III)\nnon-treated (EAC) inoculated alone. There was no mutual interaction between schistosomiasis infection and\ntumor burden. Also, whereas, PZQ did not affect on the antitumor parameters, cisplatin even at low doses had\nanti-schistosomal effects.

Open-access reader

About this research paper

What this paper is about

Schistosomiasis is the third most devastating tropical disease worldwide caused by blood flukes of the genus\nSchistosoma. Praziquantel (PZQ) is the drug of choice for treating all species of schistosomes. However, PZQ kills only\nadult Schistosoma worms, not immature stages. The inability of PZQ to abort early infection or prevent re-infection, and\nthe lack of prophylactic effect prompt the need for novel drugs and strategies for the prevention of schistosomiasis.\nTumor burden can be developed in Schistosoma-infected patients. The present study aimed to determine the host\nresponses to mutual interaction between cancer, represented by Ehrlich ascites, and infection, represented\nby Schistosomiasis. Mice infected with Schistosoma and challenged with tumor 4-5 weeks later showed the same\nanti-schistosomal (worm and egg burden) and antitumor (total tumor cell count and mouse survival) parameters\nwhen compared to mice infected with Schistosoma alone or challenged with tumor cells alone. As expected,\ncombinatorial treatment with PZQ and cisplatin of Schistosoma-infected mice that were challenged with tumor cell\nline decreased the tumor burden as well as the worm and egg burden after treatment as compared to the non-treated\ncontrols; while the worm burden and egg counts were significantly decreased (P <0.001) in treated group (VI) treated\nwith cisplatin (0.5 mg/kg), group (VII) treated with cisplatin (2 mg/kg), group (VIII) treated with PZQ/ cisplatin\n(0.5 mg/kg) and group (IX) treated with PZQ / cisplatin (2 mg/kg) by 44.55% , 74%, 100% and 97.8% in worm burden,\nand by 47%, 78.7%, 96% and 97% in liver egg count , respectively than that of group (II) non treated S. mansoni\ninfected alone and (IV) non treated S. mansoni/EAC alone. Also, Group IX caused a significant reduction\n(P <0.05) in worm burden than that of group VI. Also, total ascetic volume and the tumor cell counts in Ehrlich's\nascites carcinoma (EAC)-cells were significantly decreased (P <0.001) in groups VIII and IX than that of the group (III)\nnon-treated (EAC) inoculated alone. There was no mutual interaction between schistosomiasis infection and\ntumor burden. Also, whereas, PZQ did not affect on the antitumor parameters, cisplatin even at low doses had\nanti-schistosomal effects.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Schistosomiasis is the third most devastating tropical disease worldwide caused by blood flukes of the genus\nSchistosoma. Praziquantel (PZQ) is the drug of choice for treating all species of schistosomes. However, PZQ kills only\nadult Schistosoma worms, not immature stages. The inability of PZQ to abort early infection or prevent re-infection, and\nthe lack of prophylactic effect prompt the need for novel drugs and strategies for the prevention of schistosomiasis.\nTumor burden can be developed in Schistosoma-infected patients. The present study aimed to determine the host\nresponses to mutual interaction between cancer, represented by Ehrlich ascites, and infection, represented\nby Schistosomiasis. Mice infected with Schistosoma and challenged with tumor 4-5 weeks later showed the same\nanti-schistosomal (worm and egg burden) and antitumor (total tumor cell count and mouse survival) parameters\nwhen compared to mice infected with Schistosoma alone or challenged with tumor cells alone. As expected,\ncombinatorial treatment with PZQ and cisplatin of Schistosoma-infected mice that were challenged with tumor cell\nline decreased the tumor burden as well as the worm and egg burden after treatment as compared to the non-treated\ncontrols; while the worm burden and egg counts were significantly decreased (P <0.001) in treated group (VI) treated\nwith cisplatin (0.5 mg/kg), group (VII) treated with cisplatin (2 mg/kg), group (VIII) treated with PZQ/ cisplatin\n(0.5 mg/kg) and group (IX) treated with PZQ / cisplatin (2 mg/kg) by 44.55% , 74%, 100% and 97.8% in worm burden,\nand by 47%, 78.7%, 96% and 97% in liver egg count , respectively than that of group (II) non treated S. mansoni\ninfected alone and (IV) non treated S. mansoni/EAC alone. Also, Group IX caused a significant reduction\n(P <0.05) in worm burden than that of group VI. Also, total ascetic volume and the tumor cell counts in Ehrlich's\nascites carcinoma (EAC)-cells were significantly decreased (P <0.001) in groups VIII and IX than that of the group (III)\nnon-treated (EAC) inoculated alone. There was no mutual interaction between schistosomiasis infection and\ntumor burden. Also, whereas, PZQ did not affect on the antitumor parameters, cisplatin even at low doses had\nanti-schistosomal effects.

Key concepts: Praziquantel, Schistosomiasis, Schistosoma, Cisplatin, Schistosoma mansoni, Biology, Immunology, Helminthiasis

Related papers

Back to paper searchBrowse research topicsOriginal source
Cisplatin augments the anti-schistosomal effect of praziquantel in a schistosoma-infected cancer model — Research Paper | ScholarLens